EZZ Life Science Holdings (ASX:EZZ) Creating health supplements that meet identified consumer demand
EZZ Life Science Holdings (ASX:EZZ) is a life science company focussed on genomic research and development, addressing four key human health challenges: genetic longevity, human papillomavirus (HPV), children’s care, and weight management. The Company formulates, produces and distributes health supplements under the brand of EZZ, and is also an exclusive distributor of skin care products. […]
FBR Limited (ASX:FBR): Brick laying robot systems developer revolutionising building construction
FBR Limited (ASX:FBR) designs, develops and builds dynamically stabilised robots. These robots are designed to work outdoors and use the Company’s proprietary core Dynamic Stabilisation Technology® platform, or DST® for short. The first application of DST® is Hadrian X®, a bricklaying robot that builds structural walls faster, safer, more accurately and with less wastage than […]
PharmAust Limited (ASX:PAA): Developing new treatments for neurodegenerative diseases
PharmAust ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel for amyotrophic lateral sclerosis, the most common form of motor neurone disease. It has recently realised significant milestones in the development of monepantel for this sclerosis. These achievements include a recent study that could potentially lead […]
Short Video: Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours
Arovella Therapeutics (ASX:ALA) is a biotechnology company focused on developing its invariant Natural Killer T – or iNKT for short – cell therapy platform. The Company is now targeting the creation of products premised on this platform that treat blood cancers and solid tumours. Arovella Therapeutics’ lead product is ALA-101, which consists of iNKT cells […]
August 20, 2024: TSN’s ASX weekly wrap
TSN weekly wrap | Despite the fall in the market last week, the ASX made a slight recovery this week. For the week, the index jumped 193.4 points, or 2.4 per cent, as profits broadly delivered on expectations and bond yields eased #ASX #ASXStocks #investment #australianstockhorse #stockshow #investing #asxweeklywrap #recession
Frontier Energy (ASX:FHE) appoints former Western Australia Premier as Non-Executive Chairman
Frontier Energy (ASX:FHE; OTCQB: FRHYF) has appointed the former Western Australian Premier, Mark McGowan AC, the 30th Premier of Western Australia, as Non-Executive Chairman. McGowan AC will be appointed as Non-Executive Chairman as Frontier transitions from renewable electricity developer to major renewable energy producer McGowan brings a deep understanding of WA’s electricity landscape and key […]
Globe Metals & Mining (ASX:GBE): CDA signed with communities surrounding the Kanyika Project
Globe Metals & Mining (ASX: GBE) has signed the Community Development Agreement (CDA) with the representatives of the qualified communities surrounding the Company’s Kanyika Niobium Project. 🖊️Signed a Community Development Agreement (CDA) with representatives of communities surrounding the Kanyika Project 🤝The signing ceremony was attended by various senior dignitaries. 📍The CDA sets out the guidelines […]
What’s Hot – LRS, ODY, ARV, LSA, OSL, PDI & LTP
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – LRS, ODY, ARV, LSA, OSL, PDI & LTP What’s Not – RGT What’s Hot LRS – Latin Resources Limited today closed up 54% to finish at 18.5c on $39m stock traded. The reason they were up […]
What’s Hot – LVH, AQC, APX, WTM, PCL, ION, NOX & LRS
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – LVH, AQC, APX, WTM, PCL, ION, NOX & LRS What’s Not – AUK What’s Hot LVH – LiveHire Limited today closed up 88% to finish at 4.5c on $3.8m stock traded. The reason they were up […]
Noxopharm (ASX:NOX) announces significant CRO-67 results in complex pancreatic cancer studies
Noxopharm (ASX:NOX) has announced encouraging new data regarding its CRO-67 preclinical drug for pancreatic cancer. CRO-67 targets pancreatic cancer in a different and innovative way. The latter cancer is especially difficult to treat because tumours are surrounded by a dense barrier of cells that protects them from anti-cancer drugs, as well as from the body’s […]